🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🧵Just in time for #FluorescenceFriday: New research from the Venkataramani lab Cell maps how brain tumor cells create extensive neural networks in glioblastoma. Check out our paper here: authors.elsevier.com/sd/article/S00… Ekin Reyhan Svenja Tetzlaff 1/15

“By targeting the crosstalk between glioblastoma and vascular endothelial cells, we can develop treatments that prevent the tumor from adapting and surviving," emphasizes UCLA Health's Dr. Harley Kornblum, co-senior author of a new study in nature: bit.ly/40ird5i #GBM

A metabolic pathway for improving adoptive cellular therapy dlvr.it/THPBFJ

Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy go.nature.com/4gYcS4Z

Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding dlvr.it/THPSFV

The most quoted paper in Cancer is now published: Cancer Statistics, 2025 acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

Plasma cell and cancer stem cell crosstalk in glioblastoma dlvr.it/THQKR5

Adaptations of neutrophils in cancer dlvr.it/THQfrR

A fascinating paper shows that TAMs (and not tumor cells) are responsible in the progression from progenitor-exhausted to terminally-exhausted T cell states. #CancerImmunotherapy #GBM #TAMs sciencedirect.com/science/articl…

NEW content online! Metabolic interplays between the tumour and the host shape the tumour macroenvironment bit.ly/3DW7Kj9

Cancer statistics 2025 are in with alarming results: cancer impacting younger, more female, and racial disparities in mortality persist. acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…

Looking forward co-chairing the 6th Annual Glioblastoma Drug Development Summit. Pharma experts, Neurosurgeons, Neurooncologists and importantly patients and patients advocates come together to discuss the latest breakthroughs in tackling glioblastoma. ter.li/y0rz3s

#REVIEW 🚨 Hanahan, Michielin & Pittet discuss how, nearly all cell types in the tumour microenvironment can be programmed to mediate — as functionally distinct subtypes — immunosuppressive programmes. 📖 👇 bit.ly/4gg4rRn

For readers interested in bispecific antibodies as cancer therapies, here's a comprehensive review nature.com/articles/s4157… rdcu.be/d8sNz

On #WorldCancerDay, we honor the courage of those battling cancer and reaffirm our dedication AstraZeneca and Alexion to drive progress in rare cancer to give hope to patients who need it most. #RareCancers #CancerCare #Glioblastoma #DiffuseMidlineGliomas #DIPG #Sarcoma

Ultrasound neurotechnologies moving quickly to the clinic, a nice review article on the use of ultrasound in different applications highlighting low-intensity focused ultrasound to open the BBB to enhance delivery of therapeutics to the brain.

I had the honor of chairing the #GBM Summit in Boston where experts from patient advocacy, academia, biotech and pharma were brought together to explore advancements in GBM research and treatment. AstraZeneca Alexion Pharmaceuticals U.S. #rarecancer #waragainstGBM

On #RareDiseaseDay, we Alexion Pharmaceuticals U.S. and AstraZeneca AstraZeneca renew our commitment to those impacted by #raredisease, especially #rarecancer. Together, we’re making a difference. 💙 #RareCancer #RareDisease #HopeInResearch #PatientCentric #AstraZeneca #Alexion

We proudly stand with the rare disease community, highlighting their resilience and inspiring our continued efforts to tackle the long diagnosis timeline and life-changing treatments. #RareDiseaseDay

A groundbreaking case study that may redefine GBM immunotherapy! The first report on upfront neoadjuvant administration of #immunecheckpoint inhibitors in #GBM followed by tumor resection. Patient remains recurrence-free after 17months. nature.com/articles/s4159…